Targeting oxidative stress in cancer
Lawless, M. W., O'Byrne, Kenneth J., & Gray, Stephen G. (2010) Targeting oxidative stress in cancer. Expert Opinion on Therapeutic Targets, 14(11), pp. 1225-1245.
Importance of the field: Reactive oxygen species (ROS) occur as natural by-products of oxygen metabolism and have important cellular functions. Normally, the cell is able to maintain an adequate balance between the formation and removal of ROS either via anti-oxidants or through the use specific enzymatic pathways. However, if this balance is disturbed, oxidative stress may occur in the cell, a situation linked to the pathogenesis of many diseases, including cancer.
Areas covered in this review: HDACs are important regulators of many oxidative stress pathways including those involved with both sensing and coordinating the cellular response to oxidative stress. In particular aberrant regulation of these pathways by histone deacetylases may play critical roles in cancer progression.
What the reader will gain: In this review we discuss the notion that targeting HDACs may be a useful therapeutic avenue in the treatment of oxidative stress in cancer, using chronic obstructive pulmonary disease (COPD), NSCLC and hepatocellular carcinoma (HCC) as examples to illustrate this possibility.
Take home message: Epigenetic mechanisms may be an important new therapeutic avenue for targeting oxidative stress in cancer. © 2010 Informa UK, Ltd.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Cancer, Epigenetics, Histone deacetylase, Oxidative stress, 4 phenylbutyric acid, 5 aza 2' deoxycytidine, azacitidine, bevacizumab, bortezomib, budesonide, carboplatin, cisplatin, corticosteroid, docetaxel, doxorubicin, erlotinib, folinic acid, gemcitabine, interferon, n (2 aminophenyl) 4 (3 pyridinylmethoxycarbonylaminomethyl)benzamide, navelbine, paclitaxel, panobinostat, pemetrexed, pivaloyloxymethyl butyrate, romidepsin, rosiglitazone, salinosporamide A, sorafenib, sulforaphane, theophylline, unindexed drug, valproic acid, vorinostat, antineoplastic activity, asthma, cancer chemotherapy, cancer inhibition, cancer prevention, chronic hepatitis, chronic obstructive lung disease, clinical trial, corticosteroid therapy, DNA modification, drug mechanism, drug targeting, enzyme activity, gene expression regulation, genetic epigenesis, genetic risk, hepatitis B, hepatitis C, human, liver carcinogenesis, liver cell carcinoma, lung carcinogenesis, lung non small cell cancer, molecularly targeted therapy, nonhuman, protein processing, review, transcription initiation, Acetylation, Animals, Anticarcinogenic Agents, Antineoplastic Agents, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Drug Design, Epigenesis, Genetic, Histone Acetyltransferases, Histone Deacetylase Inhibitors, Histone Deacetylases, Histones, Humans, Liver Neoplasms, Protein Processing, Post-Translational|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2010 Informa Healthcare|
|Deposited On:||06 Dec 2013 03:51|
|Last Modified:||13 Mar 2014 01:49|
Repository Staff Only: item control page